Share

SPECTAlung: improving clinical trial access for patients with thoracic tumors

Hear Dr Jessica Menis and Dr Benjamin Besse to talk to ecancertv at WIN 2015 about SPECTAlung.

The first patients with thoracic malignancies are now entering SPECTAlung (EORTC trial 1335). Through SPECTAlung, eligible patients can be efficiently allocated to relevant therapeutic biomarker-driven clinical trials.

SPECTAlung is a standardized, quality-assured molecular screening platform for tumor characterization and storage of human biological material for the purpose of integrating new biomarkers into clinical trials and optimizing access of patients to therapeutic biomarker-driven clinical trials.

SPECTAlung plans to recruit 500 patients with pathologically confirmed lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage during its first year. In subsequent years, 500-1000 patients will be recruited per year.

SPECTAlung, coordinated by the EORTC Lung Cancer Group in collaboration with the European Thoracic Oncology Platform (ETOP) and the EORTC Pathobiology Group, is being conducted at 18 sites located in twelve countries: Belgium, Denmark, France, Germany, Ireland, Italy, Poland, Slovenia, Spain, Switzerland, The Netherlands, and the United Kingdom.

SPECTAlung is supported by InBev Baillet-Latour.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023